Willard Dere Ph.D.
Professor of Medicine, Executive Director of Personalized Health, Co-Director, Center for Clinical and Translational Science at the University of Utah. Board Member of BioMalin Pharmaceutical, Ocera Therapeutics and Radius Health. Former VP of Eli Lilly. As SVP of Global Development at Amgen, he was responsible for the clinical development of Raloxifene and other drugs for cancer, inflammation and kidney diseases.MD, University of California, Davis.



Arindam Bose Ph.D.
Over 30 years of experience in the pharmaceutical industry and elected to the National Academy of Engineering. Long-time consultant for bio-products R&D and manufacturing, he is committed to innovation in the manufacturing of biologics and serves professional social groups in the biopharmacy industry. Former Project Leader, Executive Director, VP of External Affairs and Biosimilar Strategy of Pfizer, responsible for clinical and commercial manufacturing strategies. AIMBE, AIChE, ACS member. PhD, Purdue University.


Tse Wen Chang, PhD
Over 40 years of experience spanning academia and industry. He founded Tanoxand served as VP of R&D and as a board member, focusing on developing new drugsbased on antibody structure. He also discovered anti-IgE therapeutics, leading to thedevelopment of Xolair, a drug indicated for many IgE-mediated diseases. He acquired The World Academy of Sciences (TWAS) Prize in Medical Sciences and was selectedas Honorary Fellow by the American College of Allergy, Asthma, and Immunology(ACAAI) twice. PhD, Harvard University. Postdoctoral Fellow, MIT.


Dan Wu Ph.D.
Tenured Professor of Pharmacology at Yale University. Member of China's 1,000 Talents Program. PhD from Clarkson University. He carried out research of Signal Transduction at Caltech and Yale, publishing over 100 articles & reviews in top scientific journals like Nature and Cell. He has undertaken a total of 24 research projects, including 5 sponsored by the NIH.